Clinical Research Directory

Inclusion Criteria: * Ethnic origin European, Middle Eastern, North African and whose 2 parents are from Europe, Middle East, North Africa only as there is a difference in BMD according to ethnicity * Person affiliated to or benefiting from a social security scheme * Free, informed consent signed by the participant and the investigator (on the day of inclusion and before any examination required by the research). Exclusion Criteria: * Patients presenting one of the following major risk factors: * Fragility fracture defined as a spontaneous or low-kinetic fracture (≤ one fall from height) * Hip fracture in a first-degree relative * Early menopause (\< age 40), Hysterectomy (complete \< age 40), Primary amenorrhea (absence of menstruation before age 15), Current amenorrhea of more than 3 months without contraceptive if patient is under age 40 * Treatments : Prolonged corticosteroid therapy \> 3 months or \> 1 g (cumulative dose) * Immobilization of more than 3 months, less than 12 months old * Patients presenting one of the following pathologies affecting bone, muscle or adipose tissue: * Chronic inflammatory bowel disease (IBD) (Crohn's disease, ulcerative colitis) and untreated celiac disease * Renal insufficiency on dialysis or patients with nephrology follow-up * Known hypercalciuria * Osteomalacia, rickets, osteogenesis imperfecta * Osteopathy (Paget's disease, osteopetrosis, etc.) * Chronic inflammatory rheumatism * Haemopathy, neoplasia * Hepatic insufficiency or chronic hepatitis * Endocrinopathy: dysthyroidism, hypogonadism, hypercorticism, untreated acromegaly. * Anorexia nervosa * Hyperparathyroidism (even if controlled) * History of digestive surgery (bariatric, gastrectomy, digestive resection other than appendectomy, etc.) * History of organ transplant * Chronic infectious disease (HIV, etc.) * Weight loss of more than 10 kg in the last 6 months * Paresis, marked lameness or unloading of a limb or prolonged immobilisation of more than one month in the last 12 months All patients on any treatment that may affect bone mass or body composition: * Biphosphonates (Alendronate (Fosamax® and generics), Risedronate (Actonel® and generics), Zoledronate (Aclasta® and generics) * Teriparatide (Forsteo®) * Denosumab (Prolia®) * Selective oestrogen receptor modulator (Clomifen, Tamoxifen, Toremifen, Raloxifen) * Anabolic steroids. * Strontium ranelate * Carbamazepine * Phenobarbital * Immunosuppressants * Antiepileptics All patients with one of the following anomalies in the measurement area: * Major deformities of the wrist, hip or vertebrae * Compression of the vertebral bodies, cementoplasty * Prosthesis, implant (breast, buttock, etc.), foreign body * Hip paraosteoarthropathy * Injection of radiological contrast product, barium enema, nuclear medicine examination within 10 days Miscellaneous : * Intensive sport (more than 10 h/week). * Extreme BMI (BMI \< 18, BMI \> 35 kg/m²). * Loss of autonomy * Pregnant, parturient or breast-feeding woman * Participation in an interventional study involving a drug or medical device or a category 1 RIPH in the 3 months prior to inclusion.